GlassScriptPhysician profile
Michelle Huggins
NPI 1316957939
$1,360.75
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $446 · 2021: $422 · 2022: $176.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $328.89 | 2019-2022 | |
| Novo Nordisk INC | $328.87 | 2019-2021 | |
| Pfizer INC. | $221.94 | 2019-2022 | |
| Glaxosmithkline, LLC. | $134.97 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $86.26 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $51.38 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.73 | 2019-2021 | |
| Eisai INC. | $24.54 | 2021 | |
| Merz North America, INC. | $23.61 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.65 | 2022 | |
| Shield Therapeutics INC | $21.54 | 2022 | |
| Vanda Pharmaceuticals INC. | $20.63 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.42 | 2020 | |
| Astellas Pharma US INC | $16.97 | 2019 | |
| Abbvie INC. | $13.49 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $12.86 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Huggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.